Business Description
Rocket Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US77313F1066
Total Employee Number:
202Description
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.83 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.13 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 15.5 | |||||
3-Year EPS without NRI Growth Rate | 15.3 | |||||
3-Year FCF Growth Rate | 14.5 | |||||
3-Year Book Growth Rate | -25.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 88.29 | |||||
9-Day RSI | 79.12 | |||||
14-Day RSI | 70.78 | |||||
3-1 Month Momentum % | -18.59 | |||||
6-1 Month Momentum % | -16.47 | |||||
12-1 Month Momentum % | 0.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.12 | |||||
Quick Ratio | 6.12 | |||||
Cash Ratio | 5.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11 | |||||
Shareholder Yield % | 0.14 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -65.63 | |||||
ROA % | -55.81 | |||||
ROIC % | -139.41 | |||||
3-Year ROIIC % | 9.87 | |||||
ROC (Joel Greenblatt) % | -277.96 | |||||
ROCE % | -60.62 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.76 | |||||
Price-to-Tangible-Book | 2.42 | |||||
EV-to-EBIT | -1.44 | |||||
EV-to-EBITDA | -1.52 | |||||
EV-to-Forward-Revenue | 7.85 | |||||
EV-to-FCF | -1.67 | |||||
| Price-to-Net-Current-Asset-Value | 4.09 | |||||
| Price-to-Net-Cash | 4.31 | |||||
Earnings Yield (Greenblatt) % | -69.44 | |||||
FCF Yield % | -42.88 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RCKT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rocket Pharmaceuticals Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.87 | ||
| Beta | 0.2549 | ||
| 3-Year Sharpe Ratio | -0.54 | ||
| 3-Year Sortino Ratio | -0.69 | ||
| Volatility % | 64.35 | ||
| 14-Day RSI | 70.78 | ||
| 14-Day ATR ($) | 0.214933 | ||
| 20-Day SMA ($) | 3.1035 | ||
| 12-1 Month Momentum % | 0.35 | ||
| 52-Week Range ($) | 2.53 - 5.45 | ||
| Shares Outstanding (Mil) | 109.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rocket Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rocket Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 125 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 34 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 10:00 | 2.70 (-2.53%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 08:10 | 2.92 (+0.34%) | ||
| General meeting for 2026 | 2026-05-20 09:00 | 2.92 (-4.89%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 3.86 (+7.82%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 09:20 | 5.11 (+15.09%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 11:10 | 5.01 (+9.15%) | ||
| Annual report for 2025 | 2026-02-26 | 4.33 (+0.70%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 4.33 (+0.70%) |
Show
Entries
Rocket Pharmaceuticals Inc Frequently Asked Questions
What is Rocket Pharmaceuticals Inc(RCKT)'s stock price today?
The current price of RCKT is $3.84. The 52 week high of RCKT is $5.45 and 52 week low is $2.53.
When is next earnings date of Rocket Pharmaceuticals Inc(RCKT)?
The next earnings date of Rocket Pharmaceuticals Inc(RCKT) is 2026-08-07 Est..
Does Rocket Pharmaceuticals Inc(RCKT) pay dividends? If so, how much?
Rocket Pharmaceuticals Inc(RCKT) does not pay dividend.
Guru Commentaries on NAS:RCKT
No articles.
Press Release
Articles on Rocket Pharmaceuticals Inc
No articles.
Headlines
See More- 1
Jun 12, 2026
Rocket Pharma updates cash position after selling priority review voucher
Seeking Alpha • 6:31am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers